162 related articles for article (PubMed ID: 26604072)
1. Pharmacokinetics, safety and tolerability of the novel, selective mineralocorticoid receptor antagonist finerenone - results from first-in-man and relative bioavailability studies.
Lentini S; Heinig R; Kimmeskamp-Kirschbaum N; Wensing G
Fundam Clin Pharmacol; 2016 Apr; 30(2):172-84. PubMed ID: 26604072
[TBL] [Abstract][Full Text] [Related]
2. A Phase 1 Study of Ensitrelvir Fumaric Acid Tablets Evaluating the Safety, Pharmacokinetics and Food Effect in Healthy Adult Populations.
Shimizu R; Sonoyama T; Fukuhara T; Kuwata A; Matsuo Y; Kubota R
Clin Drug Investig; 2023 Oct; 43(10):785-797. PubMed ID: 37798608
[TBL] [Abstract][Full Text] [Related]
3. Effect of Food, Crushing of Tablets, and Antacid Coadministration on Maribavir Pharmacokinetics in Healthy Adult Participants: Results From 2 Phase 1, Open-Label, Randomized, Crossover Studies.
Sun K; Ilic K; Xu P; Ye R; Wu J; Song IH
Clin Pharmacol Drug Dev; 2024 Jun; 13(6):644-654. PubMed ID: 38708555
[TBL] [Abstract][Full Text] [Related]
4. The Pharmacokinetics of the Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone.
Heinig R; Eissing T
Clin Pharmacokinet; 2023 Dec; 62(12):1673-1693. PubMed ID: 37875671
[TBL] [Abstract][Full Text] [Related]
5. Safety, Tolerability, and Pharmacokinetics of Valemetostat Tablets and the Effect of Food on Valemetostat Pharmacokinetics in Healthy Subjects: Two Phase 1 Studies.
Tachibana M; Matsuki S; Toyama K; Maekawa Y; Fukae M; Shimizu T; Tsutsumi J; Shinohara S; Ishizuka H
Clin Pharmacol Drug Dev; 2024 Jan; 13(1):77-86. PubMed ID: 37565616
[TBL] [Abstract][Full Text] [Related]
6. Clinical pharmacokinetics of doxazosin in a controlled-release gastrointestinal therapeutic system (GITS) formulation.
Chung M; Vashi V; Puente J; Sweeney M; Meredith P
Br J Clin Pharmacol; 1999 Nov; 48(5):678-87. PubMed ID: 10594469
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and Macrophage Inhibitory Cytokine-1 Pharmacodynamics of the Murine Double Minute 2 Inhibitor, Navtemadlin (KRT-232) in Fed and Fasted Healthy Subjects.
Wong S; Krejsa C; Lee D; Harris A; Simard E; Wang X; Allard M; Podoll T; O'Reilly T; Slatter JG
Clin Pharmacol Drug Dev; 2022 May; 11(5):640-653. PubMed ID: 35172043
[TBL] [Abstract][Full Text] [Related]
8. Two-Part Phase 1 Study to Evaluate the Taste Profile of Novel Belumosudil Oral Suspensions and Assess the Relative Bioavailability and Food Effect of the Selected Belumosudil Oral Suspension Compared With Oral Tablet Reference in Healthy Male Participants.
Schueller O; Regev G; Singh N; Willson A; Beville M; Kanji N; Lohmer L; Patel J
Clin Pharmacol Drug Dev; 2024 May; 13(5):491-498. PubMed ID: 38345529
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of the Novel Nonsteroidal Mineralocorticoid Receptor Antagonist Ocedurenone (KBP-5074) in Individuals with Moderate Hepatic Impairment.
McCabe J; Zhang J; Yang F; Benn V
Eur J Drug Metab Pharmacokinet; 2024 Mar; 49(2):229-237. PubMed ID: 38329646
[TBL] [Abstract][Full Text] [Related]
10. A phase I, first-in-human study investigating the safety, tolerability, and pharmacokinetics of the maturation inhibitor GSK3739937.
Benn PD; Zhang Y; Kahl L; Greene TJ; Bainbridge V; Fishman C; Wen B; Gartland M
Pharmacol Res Perspect; 2023 Jun; 11(3):e01093. PubMed ID: 37269076
[TBL] [Abstract][Full Text] [Related]
11. Safety, pharmacodynamic, and pharmacokinetic characterization of vericiguat: results from six phase I studies in healthy subjects.
Boettcher M; Thomas D; Mueck W; Loewen S; Arens E; Yoshikawa K; Becker C
Eur J Clin Pharmacol; 2021 Apr; 77(4):527-537. PubMed ID: 33125516
[TBL] [Abstract][Full Text] [Related]
12. The Oral Bioavailability and Effect of Various Gastric Conditions on the Pharmacokinetics of Dersimelagon in Healthy Adult Volunteers.
Ogawa K; Ide R; Belongie K; Tsuda M; Kawanishi H; Teng R; Ogasawara A
Clin Pharmacol Drug Dev; 2023 May; 12(5):493-501. PubMed ID: 36840969
[TBL] [Abstract][Full Text] [Related]
13. Bioavailability of Melatonin after Administration of an Oral Prolonged-Release Tablet and an Immediate-Release Sublingual Spray in Healthy Male Volunteers.
Ait Abdellah S; Raverot V; Gal C; Guinobert I; Bardot V; Blondeau C; Claustrat B
Drugs R D; 2023 Sep; 23(3):257-265. PubMed ID: 37438493
[TBL] [Abstract][Full Text] [Related]
14. Safety, tolerability, pharmacokinetics and pharmacodynamics of GSK2239633, a CC-chemokine receptor 4 antagonist, in healthy male subjects: results from an open-label and from a randomised study.
Cahn A; Hodgson S; Wilson R; Robertson J; Watson J; Beerahee M; Hughes SC; Young G; Graves R; Hall D; van Marle S; Solari R
BMC Pharmacol Toxicol; 2013 Feb; 14():14. PubMed ID: 23448278
[TBL] [Abstract][Full Text] [Related]
15. The effect of food and acid-reducing agents on the pharmacokinetic profile of capivasertib: Results from a randomized, crossover study.
Miller C; Sommavilla R; Murphy D; Morris T; Khatun M; Cullberg M
Br J Clin Pharmacol; 2023 Nov; 89(11):3330-3339. PubMed ID: 37328269
[TBL] [Abstract][Full Text] [Related]
16. Phase 1 Studies to Define the Safety, Tolerability, and Pharmacokinetic and Pharmacodynamic Profiles of the Nonsteroidal Mineralocorticoid Receptor Antagonist Apararenone in Healthy Volunteers.
Nakamura T; Kawaguchi A
Clin Pharmacol Drug Dev; 2021 Apr; 10(4):353-365. PubMed ID: 32820619
[TBL] [Abstract][Full Text] [Related]
17. Clinical safety, tolerability, pharmacokinetics and effects on urinary electrolyte excretion of AZD9977, a novel, selective mineralocorticoid receptor modulator.
Erlandsson F; Albayaty M; Chialda L; Ericsson H; Amilon C; Nelander K; Jansson-Löfmark R; Wernevik L; Kjaer M; Bamberg K; Hartleib-Geschwindner J
Br J Clin Pharmacol; 2018 Jul; 84(7):1486-1493. PubMed ID: 29468715
[TBL] [Abstract][Full Text] [Related]
18. Comprehensive clinical pharmacology characterization of AZD4635 in healthy participants to support dosing considerations.
Moorthy G; Pouliot GP; Graham L; Pilling E; Jung L; Alcobi R; Zhu Y; Li Y; Sidhu S; Forte P; Mugundu G
Br J Clin Pharmacol; 2023 Sep; 89(9):2775-2787. PubMed ID: 37055936
[TBL] [Abstract][Full Text] [Related]
19. Bioavailability, pharmacokinetics, and safety of riociguat given as an oral suspension or crushed tablet with and without food.
Saleh S; Frey R; Becker C; Unger S; Wensing G; Mück W
Pulm Circ; 2016 Mar; 6(Suppl 1):S66-74. PubMed ID: 27162630
[TBL] [Abstract][Full Text] [Related]
20. Effects of meal type on the bioavailability of vutiglabridin, a novel anti-obesity agent, in healthy subjects.
Won H; Yoon DY; Lee S; Cho JY; Oh J; Jang IJ; Yoo SK; Yu KS
Clin Transl Sci; 2024 Mar; 17(3):e13744. PubMed ID: 38436494
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
